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The need for robust surveillance of antimalarial drugs is more urgent than it has ever been. In the western
region of Cambodia, artemisinin resistance has emerged in Plasmodium falciparum and threatens to
undermine the efﬁcacy of highly effective artemisinin combination therapies. Although some manfesta-
tions of artemisinin tolerance are unique to this class of drug, many of its properties mirror previous
experience in understanding and tracking resistance to other antimalarials. In this review we outline
the spectrum of approaches that were developed to understand the evolution and spread of antifolate
resistance, highlighting the importance of integrating information from different methodologies towards
a better understanding of the underlying biologic processes. We consider how to apply our experience in
investigating and attempting to contain antifolate resistance to inform our prospective assessment of
novel antimalarial resistance patterns and their subsequent spread.
 2012 Australian Society for Parasitology Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
2. The definition of antimalarial resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
3. Measuring clinical outcomes of drug treatment in malaria is complex and expensive . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
4. Sulfadoxine–pyrimethamine as a paradigm for antimalarial resistance definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1274.1. Analyzing parasites in the laboratory: parasite genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
4.2. Analyzing parasites in the laboratory: drug sensitivity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
4.3. Pharmacology matters: did the patient have enough drugs?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
4.4. SP parameters somewhat simplified clinical studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1285. Lessons learned from SP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
5.1. Integration of clinical and laboratory studies is essential. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
5.2. Technical challenges: turning data into evidence for public health. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
5.3. Logistic challenges and the growth of networks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1296. Applying the lessons learned. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
6.1. Artemisinin combination therapies, ACTs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
6.2. Resistance to ACTs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
6.3. Better tools for characterizing artemisinin resistance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
6.4. Containing the threat of artemisinin resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
Conflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131Published by Elsevier Ltd.
ersity of Washington, Seattle, WA 98195 5065, USA. Tel.: +1 206 685 9378.
ley), rprice@menzies.edu.au (R.N. Price).
Open access under CC BY-NC-ND license.
C.H. Sibley, R.N. Price / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 126–133 1271. Introduction
Antimicrobial drug resistance is one of the greatest challenges
confronting the control of clinical infectious diseases, affecting
viruses, bacteria, fungi and parasites alike. Our antimicrobial arma-
mentarium is often limited and as a result, pathogens respond to
the selective pressure of intensive drug use. Under these circum-
stances, the genetic changes that underlie resistance have a high
probability of occurring, and when the pathogen encounters the
drug, strains with those genetic changes have a much greater
chance of surviving and being transmitted to a new host. When
these conditions are met, emergence of pathogens resistant to that
drug is inevitable. The public health question is not if, but how
quickly resistance will evolve and under what conditions those
resistant pathogens will be selected and spread.
The consequences of resistance to antibacterial and antiviral
drugs have been widely publicized. The principles, approaches
and lessons learned can be applied to any of these pathogens, from
Methicillin-resistant Staphylococcus aureus, to TB or HIV. In this re-
view we use a rich set of data from studies of sulfadoxine–pyri-
methamine resistance in Plasmodium falciparum as a framework
for considering how to optimize the monitoring and surveillance
of new generation antimalarial agents. The goal is to distill lessons
that can be applied to other systems, so whenever possible, re-
views will be used rather than the primary literature; details can
be accessed by consulting the reviews.2. The deﬁnition of antimalarial resistance
Resistance is an operational rather than absolute term. A path-
ogen is deﬁned as being drug resistant when an infection that nor-
mally would have been cured by a treatment regimen survives,
multiplies and is transmitted to a new host. In this paradigm a
resistant strain is deﬁned with reference to another that is known
to be killed by that treatment (i.e. a sensitive strain). This clinical
deﬁnition is supported, or sometimes supplanted by laboratory
studies of the pathogen. For example, assays measuring drug sus-
ceptibility in vitro can be applied to identify differences between
strains. These studies can be complemented by genetic analysis
to pinpoint speciﬁc mutations that are correlated with the de-
creased susceptibility to the drug in vitro or are more common in
the pathogens that survive the standard treatment. In many cases,
the reduced susceptibility is not a single major step, but rather a
series of modest changes that progressively decrease the parasite
responsiveness to treatment. The term ‘‘resistance’’ therefore is al-
ways relative, and is used in a wide variety of contexts, the specif-
ics of which are often poorly deﬁned. The confusion created by
these different deﬁnitions of resistance has important conse-
quences for those who must make decisions about which drugs
to recommend for treatment of the disease in question.3. Measuring clinical outcomes of drug treatment in malaria is
complex and expensive
The clinical outcome of drug treatment is central in public
health decisions on treatment policy. When a patient is treated,
what is the probability that the symptoms will be resolved in a
timely way and the infection will be cleared? The clinical assess-
ment of antimalarial efﬁcacy requires an extensive (and expensive)
establishment of a clinical team in what is often a poorly resourced
endemic setting. This in vivo protocol requires enrollment of well-
deﬁned patient cohorts with uncomplicated malaria, who are
administered supervised treatment with drugs of veriﬁed quality
and followed up for a set period of time. The standard protocol
for assessment of drug efﬁcacy in falciparummalaria has long beenestablished and is regularly reviewed and revised by the WHO
(WHO, 2010).
Despite the importance of these standardized estimates, the ba-
sic clinical efﬁcacy study masks considerable complexity and can
vary markedly in its implementation. Several important factors
confound the interpretation of results. Patients are heterogeneous,
differing in age, nutritional status, immune function, drug metabo-
lism, genetic susceptibility to infection and many other factors that
cannot be tested routinely or controlled for. Because of these vari-
ations in baseline host and parasite factors some patients fail to
cure their infection even when the parasite is still intrinsically sen-
sitive, whereas other patients can clear an infection even when the
parasite exhibits reduced drug susceptibility. The WHO guidelines
set out clear inclusion and exclusion criteria to minimize these
biases, but in practice, investigators often deviate from these to
accommodate variations in the rationale of their study.
Clinical studies also differ markedly in the analytical methods
adopted. WHO guidelines allow a number of different methods of
data analysis; per protocol, modiﬁed intention to treat or survival
analysis are all used appropriately in speciﬁc situations. However,
application of these techniques even to the same data set can intro-
duce differences in derived estimates of drug efﬁcacy that can ex-
ceed 30% (Verret et al., 2009). Moreover, the complexity and
expense of clinical studies means that the number of patients stud-
ied may be constrained. Small sample sizes can result in wide con-
ﬁdence intervals in any derived efﬁcacy estimates. The reality of all
of these factors is that 100% clinical cure cannot be expected, even
under the best of circumstances, and a variety of other approaches
for identifying truly resistant pathogens are needed to provide
additional context.4. Sulfadoxine–pyrimethamine as a paradigm for antimalarial
resistance deﬁnition
Eukaryotic parasite resistance is exempliﬁed by P. falciparum.
The rise of antimalarial drug resistance has dominated global ma-
laria control programs since resistance to chloroquine was ﬁrst
documented in patients in 1959. (Contacos et al., 1965; Young
and Burgess, 1959). Chloroquine was the ﬁrst widely used modern
antimalarial (Peters, 1987), but within little more than a decade
after its introduction chloroquine resistant (CQR) P. falciparum
had emerged and begun to spread across SE Asia. In areas of high
grade CQR a new drug; Fansidar (sulfadoxine–pyrimethamine,
SP) was adopted as the recommended therapy for uncomplicated
falciparum malaria. SP was used extensively and gained a reputa-
tion as a single dose regimen that was safe, affordable and effec-
tive. However by the 1980s its clinical efﬁcacy was clearly
waning in SE Asia and alternative treatment regimens had to be de-
ployed (Peters, 1985). Chloroquine retained efﬁcacy for longer in
Africa and Latin America and as result, the ﬁrst line use of SP
was only deployed in these regions in the mid 1990s. Everywhere
SP was intensively used, the clinical efﬁcacy of SP declined rapidly
over a period of a few years (Plowe, 2003; Sibley et al., 2001).
Thus, SP resistance developed and spread ‘‘before our very eyes’’
at a time when many key tools were available to deﬁne the
mechanism and epidemiology of the resistance, and to identify
its clinical and public health consequences (Plowe, 2003).4.1. Analyzing parasites in the laboratory: parasite genes
The tools of molecular biology had a major impact on our
understanding of SP resistance. The target enzymes for both pyri-
methamine and sulfadoxine were already known from biochemical
studies of related drugs in bacteria and human cells (Hitchings,
1989; Hitchings and Burchall, 1965) A combination of genetics
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changes to be identiﬁed in the homologous P. falciparum dihydro-
folate reductase and dihydropteroate synthase genes that were
associated with poor clinical outcomes after SP treatment (Peter-
son et al., 1988; Triglia and Cowman, 1999). Molecular analysis
of parasites could be achieved by polymerase chain reaction
(PCR) to amplify the small amount of parasite DNA in a spot of
blood from an infected person and simple analytical procedures
were designed to identify the relevant genetic changes. Such pro-
cedures were relatively inexpensive and accessible, and the meth-
odology to determine these SP-resistance-related genotypes was
widely applied in the ﬁeld (Plowe et al., 1998). The prevalence of
particular alleles of the Pfdhfr and Pfdhps was measured in a wide
variety of locations, and patients infected with parasites of partic-
ular genotypes were demonstrated to have a signiﬁcantly higher
probability of failing SP treatment (Picot et al., 2009). As SP use
increased, concomitant changes were observed in the overall par-
asite population – a rising prevalence of these resistance – associ-
ated alleles in both patients and asymptomatic carriers of P.
falciparum (Plowe, 2005). The prolonged period over which SP
was adopted in various countries in Africa and Latin America pro-
vided an opportunity for developing, validating and applying these
new tools for tracking antimalarial responses temporally and geo-
graphicaly (Ariey et al., 2002; Cortese et al., 2002; Wernsdorfer and
Payne, 1991; Wongsrichanalai et al., 2002). These approaches
made ‘‘molecular epidemiology’’ of SP resistance a reality, and set
the stage for both tracking and modeling the trajectory of the resis-
tance (Hastings and Watkins, 2006; Hastings, 1997).4.2. Analyzing parasites in the laboratory: drug sensitivity
Acceptance of the molecular indicators of emerging SP resis-
tance was facilitated by studies of parasite responses to sulfadox-
ine and pyrimethamine in the laboratory. Parasites from patients
who had failed SP treatment were adapted to growth in the labo-
ratory, and the correlation between the resistant alleles of Pfdhfr
and Pfdhps and reduced susceptibility to each drug in vitro was
demonstrated clearly (Basco, 2003; Eldin de Pecoulas et al., 1995;
Mberu et al., 2000; Watkins et al., 1985). This approach allowed
resistance to each component of SP to be examined individually,
and to explore cross resistance to other drugs. Moreover, longitudi-
nal studies highlighted decreasing parasite susceptibility to sulfa-
doxine and pyrimethamine as the prevalence of the resistant
alleles increased in the population (Basco and Ringwald, 1998;
Mberu et al., 2000; Menemedengue et al., 2011).4.3. Pharmacology matters: did the patient have enough drugs?
Treatment failure does not necessarily signify parasite drug
resistance. Clinical failure often reﬂects an inadequate concentra-
tion of the drug in the patient’s blood (Barnes et al., 2008). These
‘‘pharmacological failures’’ were often overlooked, due to the logis-
tics and cost of pharmacokinetic analysis. Retrospective studies
have shown that antimalarial dosing strategies in some vulnerable
target populations frequently require adjustment. In the case of SP,
dosing was based on strategies derived from pharmacokinetic
studies conducted mainly in adults. Appropriate studies conducted
many years after SP was ﬁrst deployed suggested that young
children had been systematically under dosed, a factor that almost
certainly contributed to the rapid decline in SP efﬁcacy (Barnes
et al., 2006, 2008). The relative simplicity of the detection methods
(Hitchings et al., 1952) and the very long half-lives of both pyri-
methamine and sulfadoxine were important factors in highlighting
the crucial role that drug concentrations play in assessment of drug
efﬁcacy (Dzinjalamala et al., 2005).4.4. SP parameters somewhat simpliﬁed clinical studies
The pharmacodynamics of sulfadoxine and pyrimethamine
afforded an advantage in clinical studies. Both sulfadoxine and
pyrimethamine have long half-lives (Bell et al., 2011), providing
a signiﬁcant prophylactic value, and contributing to their ready
acceptance both by patients and providers. The fact that a com-
plete treatment of SP required only a single dose also meant that
all therapy was directly observed, and this eliminated questions
about patient compliance, an issue in many studies.
Molecular approaches have had a signiﬁcant impact in the for-
mulating the design of clinical studies of SP efﬁcacy. The WHO pro-
tocol originally recommended that patients should be followed for
14 days after treatment. The rationale was that a new infection
required about 14 days to be manifest clinically, so one could not
be sure that parasites that reappeared after 14 days were really
derived from the original infection. However, when parasites that
recurred in patients failing treatment were examined genetically,
the characteristic Pfdhfr and Pfdhps mutant alleles were observed
far more frequently than in the initial parasite sample (Diourte
et al., 1999; Doumbo et al., 2000; Mendez et al., 2007). The resis-
tant parasites had been suppressed, but not eliminated, often man-
ifesting after day 14 as late recrudescent infections. With this
insight, it became clear that SP was completely curing patients
far less frequently than had been assumed from 14 days studies.
In response to these insights, the WHO guidelines were updated
to require follow up of 28 days (WHO, 2006).5. Lessons learned from SP
5.1. Integration of clinical and laboratory studies is essential
One of the most important lessons learned from the clinical and
laboratory studies of SP, is that their value was realized only fully
when data from many studies and different approaches could be
integrated. Fig. 1 is a schematic of the interplay and integration
of these various approaches, and illustrates the role of each compo-
nent in the clear deﬁnition of resistance.
Recommendations on drug use and procurement require
knowledge of the current status of drug efﬁcacy in a country or re-
gion. When a focus of resistance to any drug is identiﬁed, addi-
tional pressing questions are immediately posed: Has resistance
arisen anywhere else? Has the focal resistance spread to other
areas? If it has spread, how fast and in what directions are the
resistant parasites moving? These same questions had been ad-
dressed in tracking the origins and spread of antimalarial resis-
tance. Pioneering studies by Clyde (1954), Payne (1987) and
Charmot et al. (1991) reviewed in Plowe (2009) had tracked the
decline in clinical efﬁcacy of pyrimethamine and chloroquine clin-
ical efﬁcacy, but integration of the new tools into the studies
opened up important new opportunities. For example, examina-
tion of the molecular signatures of resistant alleles of Pfdhfr
showed clearly that a single mutation could confer reduced sus-
ceptibility to pyrimethamine in vitro, and prolong the time to com-
plete clearance of parasites from the patient (Mendez et al., 2002;
Plowe, 2009). However, a mutant allele with two additional muta-
tions had a greater association with clinical failure (Kublin et al.,
2002). This triple mutant allele did not arise de novo in Africa,
but had been imported into East Africa from Southeast Asia,
spreading by migration throughout the continent, and rising to
high levels only as SP use intensiﬁed in a particular location
(Certain et al., 2008; Maiga et al., 2007; Noranate et al., 2007;
Roper et al., 2003, 2004). In contrast, the mutant Pfdhfr alleles in
Latin America were indigenous, but spread within the continent,
mirroring the same migration pattern had been observed with
Fig. 1. A simple decision matrix for determining whether a clinical failure is due to parasite drug resistance, or attributable to host or pharmacological factors when a valid
molecular marker for that resistance has been identiﬁed.
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more complex history for resistance to the sulfadoxine component
of SP (Mita et al., 2011; Pearce et al., 2009).
The combination of these clinical, molecular, pharmacological
and in vitro analyses allowed more precise deﬁnition of resistance
to SP, and opened the possibility for lower cost surveillance. A large
body of work carried out in many laboratories across the malaria
endemic world ﬁrmly established the utility of laboratory based
approaches as valuable indicators of drug response in the parasite
populations, their application complementing clinical data have
been used increasingly to inform local policy decisions (Laufer
et al., 2006, 2007; Nkhoma et al., 2007).
5.2. Technical challenges: turning data into evidence for public health
Observations of SP resistance clearly demonstrated that clinical
failure is often manifest long after molecular and in vitromeasures
of drug efﬁcacy herald the ﬁrst early warning signs. To harness the
power of these surrogate measures their relationships with clinical
outcomes needed to be deﬁned. However, attempts to integrate
the available supporting information required larger geographic
scale analysis of molecular, in vitro and pharmacology data to de-
rive metrics that could be applied more widely. Although a pleth-
ora of data was available it was scattered among publications,
meeting reports and WHO compilations, and in many cases not
made public at all. For the most part, only the summary outcomes
were available, often long after the studies had been completed.
The inherent heterogeneity of data meant that simply comparing
the published outputs was not sufﬁciently informative; inclusion
criteria, outcome measures, analytical methods and many other
differences precluded pooling of the information directly and its
comprehensive analysis.
5.3. Logistic challenges and the growth of networks
By the turn of the millennium it became clear that direct inte-
gration of resistance data from the spectrum of scientiﬁc ap-
proaches and pooling of data from studies over time and
geographic location would be required to maximize the impact
of the information that had been gathered. Several regional net-
works were established in the late 1990s both as independentorganizations (EANMAT, 2001) and under the auspices of the
WHO and the Roll Back Malaria initiative, but a more global ap-
proach was needed.
Based on these experiences, a large group of scientists collabo-
rated with the WHO to establish the WorldWide Antimalarial
Resistance Network, WWARN (http://www.wwarn.org/). WWARN
was initiated as a platform to provide the tools and infrastructure
for groups studying all aspects of antimalarial resistance to collab-
orate easily, and analyze studies productively (Sibley et al., 2008,
2010). It was recognized that these kinds of collaborative analysis
could only be accomplished if disparate datasets could be pooled
and examined collectively. To accommodate different study de-
signs, data formats and examined variables, the WWARN database
has been designed to receive ﬁles of individual patient or parasite
data in any format, and transform the data sets into a common for-
mat, using agreed data structures. Such a repository then allows
pooling and standardization, facilitating collaborative analyses of
the much larger combined data sets with greater statistical power.
With this approach, exploration of correlations between clinical
outcomes, patient drug levels, allelic prevalence of potential
molecular markers and in vitro drug susceptibility become feasible.
Individual studies can be incorporated into a global resource and
become a far more powerful tool for the surveillance of antimalar-
ial drug efﬁcacy, understanding the underlying biological processes
of the parasite, and monitoring temporal and geographic trends in
drug resistance.6. Applying the lessons learned
6.1. Artemisinin combination therapies, ACTs
The early 2000s saw the declining efﬁcacy of a number of drugs
that had been used as monotherapies in various regions, including
meﬂoquine, chloroquine and amodiaquine (Lim et al., 2010). New
antimalarial agents and therapeutic strategies were needed. A piv-
otal advance in the last decade has been the deployment of
artemisinin combination therapy (ACT). The artemisinins are ex-
tremely potent antimalarial agents capable of reducing the parasite
biomass by as much as 105 within 48 h of starting treatment
(White, 2004). The combination of an artemisinin derivative with
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posed to reduce the likelihood that a parasite would evolve resis-
tance to both drugs simultaneously (White and Olliaro, 1996).
In Southeast Asia, both chloroquine and SP had lost efﬁcacy by
the mid 1980s (Wongsrichanalai et al., 2002), and had been re-
placed by meﬂoquine. Resistance to meﬂoquine evolved in the
1990s, but a series of clinical trials demonstrated that the addition
of artesunate to restored efﬁcacy (Nosten et al., 2000; Price et al.,
2004), and that this was sustained over more than a decade (Carr-
ara et al., 2009). This approach gained momentum (Breman et al.,
2004; Duffy and Mutabingwa, 2004) and in 2006, WHO expert
committees advocated strongly for the wide spread deployment
of ACTs (WHO, 2006). This strategy is now recommended univer-
sally for the treatment of uncomplicated falciparum malaria
(WHO, 2010), with almost all endemic countries endorsing their
use as ﬁrst line policy.
6.2. Resistance to ACTs
In the last decade artemisinin combination therapy has become
a key component of malaria control and elimination efforts. It was
of great concern therefore when reports of declining efﬁcacy of
artesunate began to surface from the western region of Cambodia
(Lim et al., 2009; Rogers et al., 2009) and from the Thai-Myanmar
border (Carrara et al., 2009; Phyo et al., 2012; Cheeseman et al.,
2012). The mechanism of resistance to meﬂoquine had already
been identiﬁed (Price et al., 1999, 2004) so it was assumed initially
reduced efﬁcacy of the meﬂoquine-artesunate regimen reﬂected
continuing evolution of underlying meﬂoquine resistance (Alker
et al., 2007; Lim et al., 2010). However more detailed clinical stud-
ies on a small number of patients in Western Cambodia demon-
strated that many of these patients carried parasites with
markedly slower response to artemisinin alone (Dondorp et al.,
2009, 2010; Noedl et al., 2008). Delayed parasite clearance had
been shown previously to be a hallmark of chloroquine, SP and
meﬂoquine resistance (Mendez et al., 2002; Price and Nosten,
2001; ter Kuile et al., 1992). With this in mind, the reduced suscep-
tibility of these parasites to artemisinins was viewed as the ﬁrst
evidence of the development of clinically signiﬁcant resistance.
Since artemisinins are a crucial component of all ACTs, the pros-
pect of losing these drugs to artemisinin resistance was recognized
as a major public health threat (White, 2010). The WHO led the
effort to coordinate approaches for containment of these parasites,
and developed the Global Plan for Artemisinin Resistance Contain-
ment, GPARC (WHO, 2011a).
6.3. Better tools for characterizing artemisinin resistance
The surveillance strategy for artemisinin resistance was devel-
oped from early observations of the clinical response, despite
awareness of the confounding inﬂuence of both host and parasite
factors. Molecular analyses demonstrated that the genotype of
the parasites was an important determinant of slow parasite clear-
ance (Anderson et al., 2010). However, the rate of clearance of par-
asites in individual patients was idiosyncratic, depending on a
range of factors including: the initial parasite biomass, the cell cy-
cle of the particular infection and host immunity. Methods needed
to be designed which would allow standardized comparisons be-
tween individual patients and between parasite populations
(White, 2011). The initial analyses measured the rate of decline
of parasites according to the proportion of patients still parasitae-
mic at various time points after treatment (Dondorp et al., 2009;
Noedl et al., 2008). Subsequently a collaborative effort using
pooled individual data from various studies allowed the design of
a more robust and discriminating approach to standardize using
the slope of the parasite clearance response (Flegg et al., 2011).In some patients delayed clearance and late recrudescence follow-
ing ACTs can be attributed to inadequate drug concentrations (Ash-
ley et al., 2007). In response, pharmacological methods were
developed to improve the reliability of detecting artemisinins
(Hanpithakpong et al., 2009) and partner drugs (WHO, 2011b)
and these measures were added as routine components to prospec-
tive studies.
These advances helped to deﬁne more precisely the phenotype.
They also highlight an inherent conﬂict between the provision of a
robust and sensitive phenotypic assay and the design of a simple
and practical ﬁeld applied tool. For instance the analysis of parasite
clearance times requires assessment of the parasite dynamics
every 6–8 h during the ﬁrst 2–3 days after treatment, a step which
is a far more labor intensive protocol than current standard efﬁcacy
studies. An integrated analysis that allows comprehensive under-
standing of SP resistance is needed for artemisinin resistance,
and development of methods for simple, rapid identiﬁcation of
other sites with similar parasite clinical response are now a high
priority.
In the last decade there has been increasing recognition that the
analysis of blood concentrations of antimalarial drugs is a critical
parameter for deﬁning drug resistance. Full proﬁling of pharmaco-
kinetic proﬁles is rarely feasible in clinical trials due to the require-
ment for intense blood sampling. However sparse sampling at key
time points, has proved to be a reliable surrogate for the area under
the curve (AUC) for some slowly eliminated drugs; a parameter
that correlates with therapeutic failure (White et al., 2008). How-
ever, the accurate measurement of artemisinins in blood is techni-
cally demanding, and requires sophisticated equipment that is not
widely available (Dondorp et al., 2009; Lindegardh et al., 2008).
Developing capacity to perform these pharmacological assays is
also needed.
Currently, neither genotypic nor in vitro assays can distinguish
reliably parasite populations that will respond slowly to the artem-
isinins. Modern approaches for comparing whole genomes are
being applied to parasites from the Mekong and other regions with
the goal of identifying genetic markers that correlate with the slow
clearance phenotype (Campino et al., 2011). Such methods are now
being applied much earlier in drug development so that molecular
markers of resistance will be available before the novel compounds
get to the market (Wu et al., 2011), a clear step forward in detect-
ing and managing resistance to new drugs. Novel approaches for
assessing in vitro drug susceptibility are underway in several labo-
ratories focused on drug responses, and changes in transcription
and metabolic patterns (Davis et al., 2011; Mint Lekweiry et al.,
2012; Mok et al., 2011).
6.4. Containing the threat of artemisinin resistance
The major efforts to contain artemisinin resistance are focused
on the Mekong region, in the hope of preventing its spread to other
regions. Surveillance systems are being established to delineate the
spread of the slow responding parasites. Application and integra-
tion of all of the methods under development will be needed.
The WHO have proposed the Global Plan for Containment of Arte-
misinin Resistance (WHO, 2011a) in which standardized surveil-
lance strategies will be applied in other regions where similar
strains could emerge and quickly spread. Until the surrogate mark-
ers are developed, a surveillance matrix for the slow clearance phe-
notype in regions outside the Mekong will be crucial. A practical
surveillance system that includes sites representative of diverse
transmission and demographic proﬁles needs to be mounted,
based on a network of teams which can deﬁne the baseline of par-
asite clearance of artemisinin susceptible parasites and regularly
monitor and report any changes. Warning signs of slow clearance
should trigger a regional or national rapid response team which
C.H. Sibley, R.N. Price / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 126–133 131can quickly validate or dismiss local reports. The output from such
a network must be publically available in real time, and present
data in a format that is compatible with the needs of decision mak-
ers so that timely appropriate responses can be mobilized.
The scientiﬁc community has been able to track resistance to SP,
chloroquine and meﬂoquine retrospectively, but we cannot afford
to follow resistance to artemisinins and their partner drugs in
the same way. Future effort must be community-wide, intensive
and well-coordinated. Study designs need to be creatively planned
and performed in disparate areas particularly where little informa-
tion is currently available. Online provision of the necessary tools,
resources and analytical methods will facilitate this process. Shar-
ing the available data will allow subtle trends in changing pheno-
typic and genotypic trends to be appreciated in as close to real time
as possible. These goals lie at the center of the WWARN repository
which seeks to provide the platform and tools to facilitate this
process.
The task at hand is to adapt tools that have been honed from
prior experiences with drug resistance to chloroquine, SP and mef-
loquine. Complementary work has pioneered developments in
information technology and cartography, to deﬁne transmission
patterns of malaria (Elyazar et al., 2011; Gething et al., 2011a,b),
population densities and human migration (Tatem and Smith,
2010). These provide a crucial framework onto which detailed
maps can be overlaid depicting drug resistance, malaria preva-
lence, drug quality and access to antimalarial drugs. This intelli-
gence can then be integrated with the data that have been
collected on newer antimalarials, to develop predictive models
with which to develop appropriate control and containment strat-
egies (Smith et al., 2010). Only with this concerted, coordinated
approach can we gather and analyze the needed information to
optimize and apply strategies for containment of resistance to
artemisinins in a timely manner.Conﬂict of interest
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